27509880|t|Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
27509880|a|Epigenetic anticancer drugs such as histone deacetylase (HDAC) inhibitors have been combined with existing anticancer drugs for synergistic or additive effects. In the present study, we found that a very low concentration of depsipeptide, an HDAC inhibitor, potentiated the antitumor activity of 5-fluorouracil (5-FU) in a human colon cancer cell model using HCT-116, HT29, and SW48 cells via the inhibition of colony formation ability or cellular viability. Exposure to a combination of 5-FU (1.75 uM) and 1 nM depsipeptide for 24 and 48 h resulted in a 3- to 4-fold increase in activated caspase-3/7, while 5-FU alone failed to activate caspase-3/7. Microarray and subsequent gene ontology analyses revealed that compared to 5-FU or depsipeptide alone, the combination treatment of 5-FU and depsipeptide upregulated genes related to cell death and the apoptotic process consistent with the inhibition of colony formation and caspase-3/7 activation. These analyses indicated marked upregulation of antigen processing and presentation of peptide or polysaccharide antigen via major histocompatibility complex (MHC) class (GO:0002504) and MHC protein complex (GO:0042611). Compared with vehicle controls, the cells treated with the combination of 5-FU and depsipeptide showed marked induction (3- to 8.5-fold) of expression of MHC class II genes, but not of MHC class I genes. Furthermore, our global analysis of gene expression, which was focused on genes involved in the molecular regulation of MHC class II genes, showed enhancement of pro-apoptotic PCAF and CIITA after the combination of 5-FU and depsipeptide. These results may indicate a closer relationship between elevation of MHC class II expression and cellular apoptosis induced by the combination of depsipeptide and 5-FU. To the best of our knowledge, this is the first study to report that the combination of 5-FU and depsipeptide induces human colon cancer cell apoptosis in a concerted manner with the induction of MHC class II gene expression.
27509880	19	38	histone deacetylase	GeneOrGeneProduct	3065
27509880	49	61	depsipeptide	ChemicalEntity	D047630
27509880	66	80	5-fluorouracil	ChemicalEntity	D005472
27509880	93	134	major histocompatibility complex class II	GeneOrGeneProduct	3119
27509880	139	142	p21	GeneOrGeneProduct	1026
27509880	163	174	caspase-3/7	GeneOrGeneProduct	836,840
27509880	178	183	human	OrganismTaxon	9606
27509880	184	196	colon cancer	DiseaseOrPhenotypicFeature	D003110
27509880	197	204	HCT-116	CellLine	CVCL_0291
27509880	248	267	histone deacetylase	GeneOrGeneProduct	3065
27509880	269	273	HDAC	GeneOrGeneProduct	3065
27509880	437	449	depsipeptide	ChemicalEntity	D047630
27509880	454	458	HDAC	GeneOrGeneProduct	3065
27509880	508	522	5-fluorouracil	ChemicalEntity	D005472
27509880	524	528	5-FU	ChemicalEntity	D005472
27509880	535	540	human	OrganismTaxon	9606
27509880	541	553	colon cancer	DiseaseOrPhenotypicFeature	D003110
27509880	571	578	HCT-116	CellLine	CVCL_0291
27509880	580	584	HT29	CellLine	CVCL_0320
27509880	590	594	SW48	CellLine	CVCL_1724
27509880	700	704	5-FU	ChemicalEntity	D005472
27509880	724	736	depsipeptide	ChemicalEntity	D047630
27509880	802	813	caspase-3/7	GeneOrGeneProduct	836,840
27509880	821	825	5-FU	ChemicalEntity	D005472
27509880	851	862	caspase-3/7	GeneOrGeneProduct	836,840
27509880	939	943	5-FU	ChemicalEntity	D005472
27509880	947	959	depsipeptide	ChemicalEntity	D047630
27509880	996	1000	5-FU	ChemicalEntity	D005472
27509880	1005	1017	depsipeptide	ChemicalEntity	D047630
27509880	1139	1150	caspase-3/7	GeneOrGeneProduct	836,840
27509880	1261	1275	polysaccharide	ChemicalEntity	D011134
27509880	1288	1332	major histocompatibility complex (MHC) class	GeneOrGeneProduct	3123
27509880	1350	1369	MHC protein complex	GeneOrGeneProduct	3123
27509880	1458	1462	5-FU	ChemicalEntity	D005472
27509880	1467	1479	depsipeptide	ChemicalEntity	D047630
27509880	1538	1556	MHC class II genes	GeneOrGeneProduct	3119
27509880	1569	1586	MHC class I genes	GeneOrGeneProduct	3106
27509880	1708	1726	MHC class II genes	GeneOrGeneProduct	3119
27509880	1764	1768	PCAF	GeneOrGeneProduct	8850
27509880	1773	1778	CIITA	GeneOrGeneProduct	4261
27509880	1804	1808	5-FU	ChemicalEntity	D005472
27509880	1813	1825	depsipeptide	ChemicalEntity	D047630
27509880	1897	1909	MHC class II	GeneOrGeneProduct	3119
27509880	1974	1986	depsipeptide	ChemicalEntity	D047630
27509880	1991	1995	5-FU	ChemicalEntity	D005472
27509880	2085	2089	5-FU	ChemicalEntity	D005472
27509880	2094	2106	depsipeptide	ChemicalEntity	D047630
27509880	2115	2120	human	OrganismTaxon	9606
27509880	2121	2133	colon cancer	DiseaseOrPhenotypicFeature	D003110
27509880	2193	2205	MHC class II	GeneOrGeneProduct	3119
27509880	Association	D011134	3123	Novel
27509880	Negative_Correlation	3065	D047630	No
27509880	Negative_Correlation	D005472	D003110	Novel
27509880	Association	D005472	4261	Novel
27509880	Association	D005472	8850	Novel
27509880	Positive_Correlation	D005472	1026	Novel
27509880	Positive_Correlation	840	D005472	Novel
27509880	Positive_Correlation	840	D047630	Novel
27509880	Positive_Correlation	836	D005472	Novel
27509880	Positive_Correlation	836	D047630	Novel
27509880	Negative_Correlation	D047630	D003110	Novel
27509880	Association	D047630	4261	Novel
27509880	Association	D047630	8850	Novel
27509880	Cotreatment	D047630	D005472	No
27509880	Positive_Correlation	D047630	1026	Novel
27509880	Positive_Correlation	3119	D005472	Novel
27509880	Positive_Correlation	3119	D047630	Novel